Pranav Srivastava co-wrote this blog post with Jon Roffman.
In the last three years alone, the FDA has given the green light to nearly 50 new cancer drugs. We’re excited to see what 2020 has in store for this sector, as biopharma companies continue to bring these novel therapies and diagnostics to market. The fast pace of innovation in the oncology market presents increasingly complex challenges to manufacturers seeking to maximize the benefit that they can deliver to patients. We’re committed to helping our client partners and their customers thrive and ultimately improve outcomes for cancer patients. With that in mind, our oncology practice is focused on three core dimensions that will be central to oncology manufacturers in the year ahead: navigating clinical pathways that drive the majority of treatment decisions in oncology; leveraging AI to deliver more relevant and valuable information to customers at the point of care; and delivering solutions that help customers better support their patients.Read More